β-Amyloid-mediated vasoactivity and vascular endothelial damage
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease, but the role of this peptide in neurodegeneration is unclear. The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought. We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce and excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes. The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is a potent vasoconstrictor113,114 and suppresses endothelium-dependent responses, functional hyperemia, and cerebrovascular autoregulation.115–117”
In the citing paper
“As shown by pharmacological studies, these high concentrations of A b may impair local BBB integrity (58-59), which in turn may contaminate brain ISF with blood and/or plasma that possesses A b -degrading activity (48)”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [59]
In the citing paper
“Aβ4 constrict isolated cerebral and systemic blood vessels (Niwa et al., 2001; Paris et al., 2003; Thomas et al., 1996)”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Thomas et al., 1996
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease
Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith-Swintosky, V. L., & Rydel, R. E. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90009-b · Cited by 518
PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH.
Kukreja, R. C., Kontos, H. A., Hess, M. L., & Ellis, E. F. (1986) · Circulation Research · doi:10.1161/01.res.59.6.612 · Cited by 487
Bu�e, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 334
Scholz, W. (1938) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02890989 · Cited by 180
Soluble β-Amyloid Induction of Alzheimer's Phenotype for Human Fibroblast K + Channels
Etcheberrigaray, R., Ito, E., Kim, C. S., & Alkon, D. L. (1994) · Science · doi:10.1126/science.8146663 · Cited by 167
Untangling the pathophysio-chemistry of β-amyloid
Mattson, M. P. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb1195-926 · Cited by 41
Research works printed but not linked: 2
- Davignon, J., Gregg, R. & Sing, C. Atherosclerosis 8, 1–21 (1988).
- Tomimoto, H., Nakimura, S., Wakita, H., Kimura, J. & Akiguchi, I. J. Cereb. Blood Flow Metab. 14, 563–573 (1994).
Cited by
Items 401–500 of 710
Thomas, A. J., Morris, C. M., Ferrier, I. N., & Kalaria, R. N. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06353.x · Cited by 35
AN INTRODUCTION TO REACTIVE OXYGEN SPECIES AND THEIR POSSIBLE ROLES IN SUBSTANCE ABUSE
Woods, J. R., Plessinger, M. A., & Fantel, A. G. (1998) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70366-1 · Cited by 35
Interactions between nanoparticles and pathological changes of vascular in Alzheimer’s disease
Lei, T., Yang, Z., Li, H., Qin, M., & Gao, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115219 · Cited by 36
Neurovascular and neurometabolic derailment in aging and Alzheimer's disease
Lourenço, C. F., Ledo, A., Dias, C., Barbosa, R. M., & Laranjinha, J. A. N. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00103 · Cited by 40
“Additionally, Aβ peptides can impair endothelium-dependent relaxation and enhance vasoconstriction (Thomas et al., 1996; Niwa et al., 2000b, 2001) by either promoting oxidative stress in the vascular cells (Hamel et al., 2008) and/or inhibiting the production of neuronal-derived vasodilating…”
BackgroundVascular risk factors and cognitive disorders
Debette, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.022 · Cited by 35
“…may alter clearance of amyloid b (Ab) peptide, thus favoring amyloid plaque deposition, a key neuropathological feature of AD; Ab in turn was shown to be a potent vasoconstrictor, potentially contributing to impaired cerebrovascular regulation (Thomas et al., 1996; Iadecola, 2004; Zlokovic, 2005).”
Cheng, Y., Loh, Y. P., & Birch, N. P. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0807-7 · Cited by 39
“Aβ has been found to increase levels of H 2 O 2 in neurons, which is thought to lead to an imbalance between ROS and the cells' oxidant defenses (Behl et al. 1994; Thomas et al. 1996).”
Backgroundd’Uscio, L. V., Das, P., Santhanam, A. V. R., He, T., Younkin, S. G., & Katušić, Z. S. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs266 · Cited by 35
Akkawi, N. M., Borroni, B., Agosti, C., Magoni, M., Broli, M., Pezzini, A., & Padovani, A. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0689-z · Cited by 35
Arendash, G. W., Su, G. C., Crawford, F., Bjugstad, K. B., & MULLAN, M. J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00239-6 · Cited by 35
Self-citationPerutz, M. F. (1996) · Nature · doi:10.1038/380205b0 · Cited by 33
Pluta, R. M., & Amek, M. U. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3739 · Cited by 36
“Due to the fact that soluble β-amyloid peptide causes vascular constriction (Thomas et al 1996; Niwa et al 2001) and endothelial cell injury (Table 1) (Thomas et al 1996), a role for soluble β-amyloid peptide in vasospasm and blood–brain barrier changes has been suggested.”
Vascular Function in Alzheimer’s Disease and Vascular Dementia
Tachibana, H., Washida, K., Kowa, H., Kanda, F., & Toda, T. (2016) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317516653820 · Cited by 33
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease
Schirinzi, T., Lazzaro, G. D., Sancesario, G. M., Colona, V. L., Scaricamazza, E., Mercuri, N. B., Martorana, A., & Sancesario, G. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1786-8 · Cited by 33
“…Dorr et al. 2012), including the arteriolar vasoconstriction, the reduction of cerebral blood flow and the attenuation of endothelial vasodilation (Thomas et al. 1996; Iadecola 2003), which may thus induce either a brain hypoperfusion, with a consequent change in CSF pressure (Jessen et al. 2015;…”
BackgroundPeters, E. C., Gee, M. T., Pawlowski, L. N., Kath, A. M., Polk, F. D., Vance, C. J., Sacoman, J. L., & Pires, P. W. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211039592 · Cited by 33
Misfolded Proteins Recognition Strategies of E3 Ubiquitin Ligases and Neurodegenerative Diseases
Chhangani, D., Jana, N. R., & Mishra, A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8351-0 · Cited by 32
“through cell division [2, 3].”
Janssens, J., Etienne, H., Idriss, S., Azmi, A., Martin, B., & Maudsley, S. R. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00142 · Cited by 32
Leclerc, E., Sturchler, E., Vetter, S. W., & Heizmann, C. W. (2009) · Reviews in the Neurosciences · doi:10.1515/revneuro.2009.20.2.95 · Cited by 32
β‐Amyloid‐Induced Cerebrovascular Endothelial Dysfunction
Thomas, T., McLendon, C., Sutton, E. T., & THOMAS, G. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48501.x · Cited by 31
Self-citationHigh‐Density Lipoprotein Aggregated by Oxidation Induces Degeneration of Neuronal Cells
Kivatinitz, S. C., Pelsman, M. A., Del C. Alonso, A., Bagatolli, L., & Quiroga, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052102.x · Cited by 32
Amyloid-β peptide alteration of tau exon-10 splicing via the GSK3β-SC35 pathway
Chen, K.-L., Yuan, R.-Y., Hu, C., & Hsu, C. Y. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.013 · Cited by 33
“, astrocytes (Harris et al., 1996; Yang et al., 2004) and cerebral endothelial cells (Sutton et al., 1997; Thomas et al., 1996; Yin et al., 2002, 2006).”
Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies
Heim, C. C., Zhang, J., Lan, J. Q., Sieklucka, M., Kurz, T., Riederer, P. F., Gerlach, M., & Sontag, K. ‐. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00916.x · Cited by 31
beta-Amyloid vasoactivity in Alzheimer's disease.
Kalaria, R. N., & Hedera, P. (1996) · PubMed · Cited by 31
Vaisi‐Raygani, A., Rahimi, Z., Entezami, H., Kharrazi, H., Bahrhemand, F., Tavilani, H., Rezaei, M., Kiani, A., Nomanpour, B., & Pourmotabbed, T. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510701576180 · Cited by 31
Chisari, M., Merlo, S., Sortino, M. A., & Salomone, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.09.004 · Cited by 32
Apolipoprotein E gene polymorphism in cerebrovascular disease: a case–controlstudy
Luthra, K., Prasad, K., Kumar, P., Dwivedi, M., Pandey, R., & Das, N. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.620105.x · Cited by 31
Suo, Z., Su, G. C., Placzek, A. N., Kundtz, A., Humphrey, J., Crawford, F., & MULLAN, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06363.x · Cited by 30
Self-citationZhan, R., Tong, Y., Shen, J., Lang, E. W., Preul, C., Hempelmann, R. G., Hugo, H. ‐., Buhl, R. M., Barth, H., Klinge, H., et al. (2004) · Journal of Zhejiang University. Science A · doi:10.1631/jzus.2004.1262 · Cited by 29
“A4/β-protein accumulates in the affected cerebral vessel walls and damaged vascular smooth muscle and/or vascular endothelial cells, suggesting that it inhibits vascular contraction and/or platelet adhesion (Thomas et al., 1996; Behl et al., 1994).”
BackgroundA novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease
Bertoli‐Avella, A. M., Teruel, B. M., Rodríguez, J. J. L., Viera, N. G., Martinez, I. B., Severijnen, E., Joosse, M., van Duijn, C. M., Baute, L. H., & Heutink, P. (2002) · Neurogenetics · doi:10.1007/s10048-002-0136-6 · Cited by 29
Consideration of the ischaemic basis and treatment of Alzheimer's disease.
Pluta, R. M., Ułamek, M., & Jabłoński, M. (2010) · PubMed · Cited by 30
Volume Reduction in Cerebral Blood Flow in Patients with Alzheimer’s Disease: A Sonographic Study
Akkawi, N. M., Borroni, B., Agosti, C., Pezzini, A., Magoni, M., Rozzini, L., Prometti, P., Romanelli, G., Vignolo, L. A., & Padovani, A. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000071005 · Cited by 30
Laskay, G., Zarándi, M., Varga, J., Jost, K., Fónagy, A., Torday, C., Latzkovits, L., & Penke, B. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6806 · Cited by 29
Sonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer’s disease
Parashar, A., jha, D., Mehta, V., Chauhan, B., Ghosh, P., Deb, P. K., Jaiswal, M., & Prajapati, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102271 · Cited by 28
Does Aβ 42 Have a Function Related to Blood Homeostasis?
Hardy, J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9221-9 · Cited by 31
Shen, M., Hsiao, G., Fong, T., Chou, D., & Sheu, J. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.01.004 · Cited by 28
Abbatecola, A. M., Barbieri, M., Rizzo, M. R., Grella, R., Laieta, M. T., Quaranta, E., Molinari, A. M., Cioffi, M., Fioretto, P., & Paolisso, G. (2008) · The Journals of Gerontology Series A · doi:10.1093/gerona/63.9.991 · Cited by 28
“Recent reports have also demonstrated that b-amyloid interacts with endothelial cells in the production of free radicals ( 31 ).”
BackgroundIncreased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease
Piazza, F., Galimberti, G., Conti, E., Isella, V., Perlangeli, M. V., Speranza, T., Borroni, B., Pogliani, E. M., Padovani, A., & Ferrarese, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.016 · Cited by 28
“Previous literature data showed that Abeta, which is central to AD pathology, determines alterations in endothelial structure and function (Borroni et al., 2002; Thomas et al., 1996).”
Shinozaki, K., Ayajiki, K., Kashiwagi, A., Masada, M., & Okamura, T. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj04006x4 · Cited by 33
A review study on the effect of zinc on oxidative stress-related neurological disorders
Vali, R., Shirvanian, K., Farkhondeh, T., Aschner, M., Samini, F., & Samarghandian, S. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127618 · Cited by 29
Microvascular degeneration occurs before plaque onset and progresses with age in 3xTg AD mice
Quintana, D. D., Anantula, Y., Garcia, J. A., Engler-Chiurazzi, E. B., Sarkar, S. N., Corbin, D. R., Brown, C. M., & Simpkins, J. W. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.019 · Cited by 29
Daulatzai, M. A. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9643-3 · Cited by 27
Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration
Quaegebeur, A., & Carmeliet, P. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_83 · Cited by 33
“Ab has been known for some time to act as a vasoconstrictive agent (Thomas et al. 1996).”
BackgroundPotassium channel openers prevent β-amyloid toxicity in bovine vascular endothelial cells
Chi, X., Sutton, E. T., Hellermann, G., & Price, J. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01293-3 · Cited by 30
Høgh, P., Garde, E., Mortensen, E. L., Jørgensen, O. S., Krabbe, K., & Waldemar, G. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00779.x · Cited by 25
Martyn, C. N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90603-0 · Cited by 31
Role of Apolipoprotein E in Alzheimer’s Disease
Zannis, V. I., Zanni, E. E., Makrides, S. C., Kardassis, D., & Aleshkov, S. B. (1998) · Springer eBooks · doi:10.1007/978-1-4899-0133-0_13 · Cited by 27
C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer’s disease
Liao, J., Chen, G., Liu, X., Wei, Z. Z., Yu, S. P., Chen, Q., & Ye, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01556-0 · Cited by 28
“Serum Aβ levels are elevated in stroke patients [51] and Aβ exerts toxic effects on the vascular endothelium [52, 53].”
BackgroundReekes, T. H., Ledbetter, C. R., Alexander, J., Stokes, K. Y., Pardue, S., Bhuiyan, M. A. N., Patterson, J. C., Lofton, K. T., Kevil, C. G., & Disbrow, E. A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102633 · Cited by 26
Bae, O.-N., Lim, K., Han, J.-Y., Jung, B.-I., Lee, J.-Y., Noh, J.-Y., Chung, S.-M., Lee, M., Lee, J., & Chung, J. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn023 · Cited by 28
“Supporting this view in part, there are many cases of endothelial dysfunction (Davignon and Ganz, 2004; Heistad, 2006; Lee et al., 2003; Thomas et al., 1996; Wattanapitayakul et al., 2000), whereas reports on the disruption of smooth muscle function can be hardly found.”
BackgroundRoberts, A. M., Jagadapillai, R., Vaishnav, R., Friedland, R. P., Drinovac, R., Lin, X., & Gozal, E. (2016) · Physiological Reports · doi:10.14814/phy2.12953 · Cited by 29
“Cerebral amyloid angiopathy is a hallmark of AD (Thomas et al. 1996; Sutton et al. 1997) and increased Ab is recognized as a cause of ª 2016 The Authors.”
BackgroundAlzheimer's β‐amyloid vasoactivity: identification of a novel β‐amyloid conformational intermediate
Crawford, F., Soto, C., Suo, Z., Fang, C., Parker, T., Sawar, A., Frangione, B., & Mullan, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01170-3 · Cited by 26
Self-citationBrain Endothelial Cells as Pharmacological Targets in Brain Tumors
Demeule, M., Régina, A., Annabi, B., Bertrand, Y., Bojanowski, M. W., & Béliveau, R. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:2:157 · Cited by 30
Is the ischemic blood–brain barrier insufficiency responsible for full-blown Alzheimer's disease?
Pluta, R. M. (2006) · Neurological Research · doi:10.1179/016164106x130399 · Cited by 25
Cambronero, F. E., Liu, D., Neal, J. E., Moore, E. E., Gifford, K. A., Terry, J. G., Nair, S., Pechman, K. R., Osborn, K. E., Hohman, T. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.009 · Cited by 27
“, 2000), which can induce endothelial damage and changes in vascular tone (Thomas et al., 1997; Thomas et al., 1996).”
BackgroundPeripheral Routes to Neurodegeneration: Passing Through the Blood–Brain Barrier
Giannoni, P., Claeysen, S., Noè, F. M., & Marchi, N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00003 · Cited by 27
“Completing a vicious cycle, beta-amyloid deposition in the brain can provoke capillaries dysfunction (Thomas et al., 1996; Zhang et al., 1997; Iadecola et al., 1999; Deane et al., 2003, 2012; Nortley et al., 2019).”
BackgroundAxo-axonal interaction in autonomic regulation of the cerebral circulation
Lee, T. J. F., Chang, H., Lee, H. C., Chen, P. Y., Lee, Y.-U., Kuo, J. S., & Chen, M.-S. (2010) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02231.x · Cited by 26
“Abs may act on endothelial cells and vascular smooth muscle, respectively, causing endothelial dysfunction (Thomas et al. 1996, Chi et al. 1999) and potentiation of smooth muscle constriction induced by other vasoactive substances (Niwa et al. 2002, Deane et al. 2003).”
BackgroundVascular Actions of Estrogen and Alzheimer's Disease
Thomas, T., & Rhodin, J. A. G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06406.x · Cited by 27
Self-citationPeripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 25
Waigi, E. W., Webb, R. C., Moss, M. A., Uline, M. J., McCarthy, C. G., & Wenceslau, C. F. (2023) · GeroScience · doi:10.1007/s11357-023-00748-y · Cited by 28
“Aβ peptides are toxic to the brain and peripheral endothelial cells and cause cellular damage, enhance vasoconstriction, and impair endothelium-dependent vasodilation hence promoting atherosclerosis and vascular disease [21].”
BackgroundMielke, J. G., Murphy, M. P., Maritz, J., Bengualid, K. M., & Ivy, G. O. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00340-6 · Cited by 24
Bae, O., Lim, E.-K., Lim, K., Noh, J.-Y., Chung, S.-M., Lee, M.-Y., Yun, Y., Kwon, S., Lee, J., Nah, S.-Y., et al. (2008) · Environmental Research · doi:10.1016/j.envres.2008.06.012 · Cited by 24
(3-amyloid vasoactivity in Alzheimer's disease
Gurwitz, D., Kalaria, R. N., & Hedera, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91731-6 · Cited by 24
The Cardiac Dysfunction Caused by Metabolic Alterations in Alzheimer's Disease
Murphy, J., Le, T. N. V., Fedorova, J., Yang, Y., Krause‐Hauch, M., Davitt, K., Zoungrana, L. I., Fatmi, M. K., Lesnefsky, E. J., Li, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850538 · Cited by 23
“For example, Tg2576 mice which express a highly elevated level of APP is associated with the development of cognitive impairment and ROS-mediated endothelial dysfunction with perfusion reduction (2, 15).”
Andrade-Guerrero, J., Orta‐Salazar, E., Salinas‐Lara, C., Sánchez-Garibay, C., Rodríguez-Hernández, L. D., Vargas-Rodríguez, I., Barron-Leon, N., Ledesma-Alonso, C., Díaz-Cintra, S. Y., & Soto-Rojas, L. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311134 · Cited by 24
“The vascular Aβ deposition has been associated with NVU components degeneration and dysfunction: endothelial cell [39,40], astrocytic end-feet [7], pericytes [7,41], and smooth muscle [7,42], and enlarged PVS [43].”
BackgroundSi, M.-L., Chen, L., Yang, D., Chen, M.-F., & Lee, T. J.-F. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600232 · Cited by 23
“In basilar arteries (without endothelial cells) in the presence of active muscle tone induced by U-46619 (0.3 mmol/L), relaxation induced by nicotine (100 mmol/L) and choline (1 mmol/L) was blocked by Ab1 40 in a concentration-dependent manner (Figures 1A–1C and 2A and 2B, n = 6).”
BackgroundInfluentialThe Clinical Application of Ozonetherapy
Bocci, V. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9234-2_9 · Cited by 31
“The possibility that Alzheimer’s disease, associated with a deposition of insoluble -amyloid aggregates, reflects an NO /superoxide imbalance has been entertained by Thomas et al. (1996).”
BackgroundLuo, F., Seifert, T. R., Edalji, R. P., Loebbert, R. W., Hradil, V. P., Harlan, J. E., Schmidt, M. U., Nimmrich, V., Cox, B. F., & Fox, G. B. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.021 · Cited by 23
Bosentan preserves endothelial function in mice overexpressing APP
Elesber, A. A., Bonetti, P. O., Woodrum, J. E., Zhu, X.-Y., Lerman, L. O., Younkin, S. G., & Lerman, A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.012 · Cited by 26
Shadlen, M., Larson, E. B., & Yukawa, M. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00115-9 · Cited by 23
β‐Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP‐Elevating Agents
Paris, D., Town, T., Parker, T. A., Humphrey, J., & MULLAN, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06397.x · Cited by 22
“We investigated the role of sGC in the vasoactivity mediated by Aβ by using a highly selective inhibitor of sGC, 1H[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ).”
MethodSelf-citationPontes‐Neto, O. M., Auriel, E., & Greenberg, S. M. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.134 · Cited by 25
The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis
Nostrand, W. E. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.020 · Cited by 22
Aβ, aging, and Alzheimer's disease: A tale, models, and hypotheses
Chaney, M. O., Baudry, J. Y., Esh, C. L., Childress, J., Luehrs, D. C., Kokjohn, T. A., & Roher, A. E. (2003) · Neurological Research · doi:10.1179/016164103101202011 · Cited by 22
Cooperation between neurovascular dysfunction and Aβ in Alzheimer’s disease
Wang, N., Yang, X., Zhao, Z., Liu, D., Wang, X., Tang, H., Zhong, C., Chen, X., Chen, W. K., & Meng, Q. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1227493 · Cited by 23
Impaired Cerebral Autoregulation in Alzheimer’s Disease: A Transcranial Doppler Study
Zhou, G., Zhao, X., Lou, Z., Zhou, S., Shan, P., Zheng, N., Yu, X., & Ma, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190296 · Cited by 22
“:3) exerts detrimental effects on cerebrovascular function [14].”
Soriano, F. X., Galbete, J. L., & Forloni, G. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00008-1 · Cited by 22
Neuroinflammation and Alteration of the Blood-Brain Barrier in Alzheimer´s Disease
Soto-Rojas, L. O., de la Cruz‐López, F., Ontiveros‐Torres, M. Á., Viramontes‐Pintos, A., Cárdenas‐Aguayo, M. D. C., Meraz‐Ríos, M. A., Salinas‐Lara, C., Florán, B., & Luna‐Muñoz, J. (2015) · InTech eBooks · doi:10.5772/60024 · Cited by 23
“Recent studies support the vascular theory to show that the brain distribution of Aβ receptors in the apical side of the BBB might be responsible for the interaction of Aβ circulating with the vascular wall and mediate its transit to the brain [115].”
ResultTakase, K. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01563-4 · Cited by 21
Cerebrovascular structure and dementia: new drug targets
Atkinson, J. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01866-6 · Cited by 26
Zhang, J., Chi, H., Wang, T., Zhang, S., Shen, T., Leng, B., Sun, H., Li, Z., & Li, F. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210216 · Cited by 21
“A (cid:2) deposition in small arteries caused by cerebral hypoperfusion could further induce cerebrovascular lesions and worsen cerebral hypoperfusion, finally leading to a vicious cycle and irreversible damage [21, 22].”
Li, S., Wang, C., Wang, Z., & Tan, J. (2021) · Aging · doi:10.18632/aging.203482 · Cited by 22
Šutalo, I. D., Bui, A., Ahmed, S., Liffman, K., & Manasseh, R. (2014) · Engineering Applications of Computational Fluid Mechanics · doi:10.1080/19942060.2014.11083311 · Cited by 20
“…and decreases the microvascular diameter as proven for rodent and human arteries (Niwa et al., 2001; Paris et al., 2003; Price et al., 1997; Suo et al., 1998; Thomas et al., 1996), a typical cerebral vasculature vasoconstriction is 10% (Niwa et al., 2001; Paris et al., 2003; Price et al., 1997).”
Bürger, S., Yafai, Y., Bigl, M., Wiedemann, P., & Schliebs, R. (2010) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.07.231 · Cited by 24
“…Mancardi et al., 1980), cerebral amyloid angiopathy, and microvascular endothelial degeneration (De la Torre, 2002; Kalaria, 2000; Soffer, 2006; Thomas et al., 1996) have frequently been observed in Alzheimer patients, from which a causal relationship between vascular mechanisms and the…”
BackgroundNavarro‐Dorado, J., Villalba, N., Prieto, D., Brera, B., Martín-Moreno, A. M., Tejerina, T., & CEBALLOS, M. L. D. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00422 · Cited by 20
Pulse pressure is associated with plasma amyloid-β transport dysfunction
Jiang, Y., Shang, S., Li, P., Chen, C., Dang, L., Wang, J., Huo, K., Deng, M., Wang, J., & Qu, Q. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001565 · Cited by 20
Platelet secretion of β-amyloid is increased in hypercholesterolaemia
Smith, C., Hyatt, P. J., Stanyer, L., & Betteridge, D. J. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02080-7 · Cited by 21
Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs
Grundman, M., Corey‐Bloom, J., & Thal, L. J. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_23 · Cited by 22
(1996) · Nature · doi:10.1038/380108b0 · Cited by 20
NOX2 in Alzheimer's and Parkinson's disease
Dustin, C. M., Shiva, S. S., Vazquez, A. L., Saeed, A., Pascoal, T. A., Cifuentes-Pagano, E., & Pagano, P. J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103433 · Cited by 20
Platelet Microparticles as Carriers of Soluble Alzheimer's Amyloid β (sAβ)
Matsubara, E., Shoji, M., Murakami, T., Abe, K., Frangione, B., & Ghiso, J. A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04836.x · Cited by 21
Inclusion Body Myositis: A View from the Caenorhabditis elegans Muscle
Rebolledo, D. L., Minniti, A. N., Grez, P. M., Fadić, R., Kohn, R. E., & Inestrosa, N. C. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8041-0 · Cited by 19
“O2 from cells, is involved in AD because it prevents the damage produced by Aβ in endothelial cells [131].”
BackgroundYou, J., Feng, L., Bao, L.-Y., Xin, M., Ma, D., & Feng, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00467 · Cited by 20
Borroni, B., Agosti, C., Martini, G., Volpi, R., Brambilla, C., Caimi, L., Luca, M. D., & Padovani, A. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.11.030 · Cited by 19
“In particular, it has been recently claimed that Ah determines a perturbation in cell–cell and cell–matrix interaction, thus predisposing to increased adhesiveness of endothelium and leukocytes [11,12].”
BackgroundThe Vasoactivity of Aβ Peptides
Crawford, F., Suo, Z., Fang, C., Sawar, A., Su, G. C., Arendash, G. W., & MULLAN, M. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48459.x · Cited by 19
Self-citationPathogenic Factors in Vascular Dementia and Alzheimer’s Disease
Engelberg, H. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080034 · Cited by 22
An Overview of Alzheimer’s Disease Research
Khachaturian, Z. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00026-6 · Cited by 19
Production of Neurotoxic Factors by Brain Endothelium in Alzheimer's Diseasea
Grammas, P., Botchlet, T., Moore, P., & Weigel, P. H. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48460.x · Cited by 20
Feasibility of in vivo 18F-florbetaben PET/MR imaging of human carotid amyloid-β
Bucerius, J. A., Barthel, H., Tiepolt, S., Werner, P., Sluimer, J. C., Wildberger, J. E., Patt, M., Hesse, S., Gertz, H., Biessen, E. A. L., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3651-2 · Cited by 20
Liu, D., Ahmet, I., Griess, B., Tweedie, D., Greig, N. H., & Mattson, M. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20964233 · Cited by 18
“The accumulation of Ab oligomers in AD brain has the potential to impair vascular endothelial function, compromise the regulation of vascular reactivity and CBF response, even before the apparent deposition of extracellular Ab plaques.(20,39,40) Deposition of Ab oligomer aggregates can trigger cerebral inflammation as…”
BackgroundResultGlucose regulates amyloid β production via AMPK
Yang, T.-T., Shih, Y.-S., Chen, Y., Kuo, Y., & Lee, C.-W. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1413-5 · Cited by 18
Is pharmacological prevention of Alzheimer's a realistic goal?
Anthony, J. C., Breitner, J. C. S., & Zandi, P. P. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.4.365 · Cited by 19
Metadata
- Authors
- Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M.
- Affiliations
- University of South Florida (US)
- Venue
- Nature
- Published
- 1996-03
- Volume
- 380
- Issue
- 6570
- Pages
- 168-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1990427131
- Cited by
- 703
- References
- 12
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 18 · 2023: 22 · 2022: 9 · 2021: 15 · 2020: 24 · 2019: 19 · 2018: 5 · 2017: 12 · 2016: 22 · 2015: 26 · 2014: 16 · 2013: 26 · 2012: 13
- FWCI
- 26.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- amyloid-beta, Alzheimer's disease, vascular endothelial cells, superoxide, free radicals, superoxide dismutase, endothelium-derived relaxing factor, lipid peroxidation, vascular tone, neurodegeneration, aging, oxidative stress
- MeSH terms
- Acetylcholine, Alzheimer Disease, Animals, Aorta, Blood Vessels, Endothelium, Vascular, Nerve Degeneration, Phenylephrine, Superoxides, Vasoconstriction, Vasoconstrictor Agents, Vasodilator Agents, Amyloid beta-Peptides, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.